NCT03870399View on ClinicalTrials.gov

Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

May 13, 2023

Study Completion Date

May 13, 2023

Conditions
Neuroendocrine TumorsProgesterone Receptor Positive TumorEstrogen Receptor Positive Tumor
Interventions
DRUG

Tamoxifen

The treatment to be used will be tamoxifen 20mg orally once daily.

Trial Locations (2)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

01525000

AC Camargo Cancer Center, São Paulo

All Listed Sponsors
collaborator

H. Lee Moffitt Cancer Center and Research Institute

OTHER

lead

AC Camargo Cancer Center

OTHER

NCT03870399 - Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression | Biotech Hunter | Biotech Hunter